Sinclair P A, Squires E J, Raeside J I, Britt J H, Hedgpeth V G
Department of Animal and Poultry Science, University of Guelph, Ontario, Canada.
J Anim Sci. 2001 Apr;79(4):1003-10. doi: 10.2527/2001.7941003x.
Three studies examined the effects of early postnatal treatment with a GnRH agonist on plasma concentrations of testosterone, dehydroepian-drosterone sulfate, 16-androstene steroids in fat and salivary glands, androstenone in fat and plasma, and testicular development of intact male pigs. The first study involved 45 7-d-old pigs assigned to three treatment groups: 1) boars administered 100 microg/kg of Lupron depot, 2) boars administered 200 microg/kg of Lupron depot, and 3) control boars receiving a saline carrier. The second study involved 20 7-d-old pigs assigned to two treatments: daily injection of 200 microL of 0.5 mg/mL Lupron from d 7 to 35 and controls treated with saline. The third study involved a total of 100 animals assigned to 10 groups of 10 based on their age at slaughter. These groups were subdivided into one of two treatments: 1) boars injected with 200 microL of 0.5 mg/mL of Lupron from d 3 to 35 and 2) control boars injected with saline. Testicular steroid hormone concentrations in plasma decreased (P < 0.01) within 7 d of GnRH agonist treatment. Following cessation of treatment, steroid levels increased to control levels and remained constant until the final rise at 5 mo. Plasma testosterone levels in the 100 microg/kg depot treatment group were higher (P < 0.05) than that of the 200 microg/kg and control group at 164 d of age. There were no differences between treatments (P > 0.05) in testicular steroid hormone levels at the end of study 2 or 3. There were no differences (P > 0.05) in concentrations of 16-androstene steroids in salivary glands between any of the treatment groups at market weight in studies 1 and 2. Fat androstenone levels measured in the third study ranged between 0.6 microg/g and 4.2 microg/g at 7 to 28 d of age. Treatment with GnRH agonist decreased plasma steroid levels and testicular development; however, by d 60 testicular size and weight were at control levels and remained similar until 180 d of age. The results of these studies indicate that daily administration of a GnRH agonist significantly decreased testicular development and steroidogenesis only during treatment, but testis growth and steroidogenesis had returned to control levels by 60 d of age in male pigs. Suppression of the early postnatal rise in testicular steroid hormones did not affect growth performance or steroid hormone levels at 5 to 6 mo of age.
三项研究考察了产后早期用促性腺激素释放激素(GnRH)激动剂治疗对完整雄性仔猪血浆睾酮、硫酸脱氢表雄酮、脂肪和唾液腺中16 - 雄烯类固醇、脂肪和血浆中雄烯酮浓度以及睾丸发育的影响。第一项研究涉及45头7日龄仔猪,分为三个治疗组:1)给予100微克/千克醋酸亮丙瑞林微球的公猪;2)给予200微克/千克醋酸亮丙瑞林微球的公猪;3)接受生理盐水载体的对照公猪。第二项研究涉及20头7日龄仔猪,分为两种治疗:从第7天至35天每天注射200微升0.5毫克/毫升醋酸亮丙瑞林,以及用生理盐水治疗的对照组。第三项研究总共涉及100只动物,根据屠宰时的年龄分为10组,每组10只。这些组再细分为两种治疗之一:1)从第3天至35天注射200微升0.5毫克/毫升醋酸亮丙瑞林的公猪;2)注射生理盐水的对照公猪。GnRH激动剂治疗后7天内,血浆中睾丸类固醇激素浓度下降(P < 0.01)。治疗停止后,类固醇水平升至对照水平并保持恒定,直到5月龄时最终升高。100微克/千克微球治疗组在164日龄时的血浆睾酮水平高于200微克/千克组和对照组(P < 0.05)。在研究2或3结束时,各治疗组睾丸类固醇激素水平无差异(P > 0.05)。在研究1和2中,任何治疗组在上市体重时唾液腺中16 - 雄烯类固醇浓度均无差异(P > 0.05)。在第三项研究中,7至28日龄时测得的脂肪中雄烯酮水平在每克0.6微克至4.2微克之间。用GnRH激动剂治疗可降低血浆类固醇水平和睾丸发育;然而,到60日龄时睾丸大小和重量已达到对照水平,并在180日龄前保持相似。这些研究结果表明,每天给予GnRH激动剂仅在治疗期间显著降低睾丸发育和类固醇生成,但雄性仔猪到60日龄时睾丸生长和类固醇生成已恢复到对照水平。抑制产后早期睾丸类固醇激素的升高并不影响5至6月龄时的生长性能或类固醇激素水平。